ASTRO's posters feature the latest scientific case studies, practice innovations and research from experts in the field of radiation oncology.

Poster presentations will be accessible to both live and virtual meeting attendees starting at 5:00 p.m. Central time on Friday, October 21, 2022. Posters can be viewed through the Conference Planner and MyASTROApp, and in the Virtual Poster Library.

To view posters in the Virtual Poster Library, you will be asked to create an account.  The library is not tied to your account.  If you created a login for past ASTRO meetings, you can use that login information again.

Poster Hall Hours

Visit the Poster Hall to peruse posters at your own pace. The Poster Hall is located in Hall 1, and can be accessed through the Exhibit Hall, or through a door off the main lobby when the Exhibit Hall is closed.

Date Time
Sunday, October 23 10:00 a.m. - 6:00 p.m.
Monday, October 24 8:45 a.m. - 6:00 p.m.
Tuesday, October 25 8:45 a.m. - 6:15 p.m.
Wednesday, October 26 8:45 a.m. - 1:45 p.m.
Poster Q&A Sessions

During scheduled times, attendees will have the opportunity to ask poster presenters questions about their research. Posters will be organized by track, as outlined below. View the Poster Q&A presentation schedule below for specific times.

The Poster Q&A Session Schedule is outlined below:

Sunday, October 23, 2022

Session Time Tracks/Group
Poster Session 1 4:45 p.m. - 6:00 p.m. Lung Cancer/Thoracic Malignancies
Diversity, Equity and Inclusion in Health Care

Monday, October 24, 2022

Session Time Tracks/Group
Poster Session 2 10:45 a.m. - 12:00 p.m. Central Nervous System
Palliative Care
Poster Session 3 3:00 p.m. - 4:00 p.m. Breast Cancer
Nonmalignant Disease
Poster Session 4 5:00 p.m. - 6:00 p.m. Radiation and Cancer Biology
Patient Reported Outcomes/QoL/Survivorship

Tuesday, October 25, 2022

Session Time Tracks/Group
Poster Session 5 12:45 p.m. - 2:00 p.m. Gastrointestinal Cancer
Sarcoma and Cutaneous Tumors
Poster Session 6 2:30 p.m. - 3:45 p.m. Genitourinary Cancer
Patient Safety
Nursing and Supportive Care
Poster Session 7 4:00 p.m. - 5:00 p.m. Digital Health Innovation
Hematologic Malignancies
Poster Session 8 5:15 p.m. - 6:15 p.m. Gynecological Cancer
Pediatric Cancer
Professional Development/Medical Education

Wednesday, October 26, 2022

Session Time Tracks/Group
Poster Session 9 10:30 a.m. - 11:45 a.m. Head and Neck Cancer
Health Services Research/Global Oncology
Poster Session 10 12:30 p.m. - 1:45 p.m. Radiation and Cancer Physics
Poster viewing for Virtual Attendees

Live virtual meeting attendees will not be able to participate in Poster Q&A Sessions. However, this does not mean that virtual attendees will miss out on hearing all about this important research! Each poster author will add audio narration to their poster, which virtual meeting attendees will be able to listen to through the virtual poster library, as well as in the Conference Planner and in the MyASTROApp.

To view posters in the Virtual Poster Library, you will be asked to create an account. The library is not tied to your account. If you created a login for past ASTRO meetings, you can use that login information again.

Poster Walks

ASTRO is bringing back Poster Walks reimagined! Poster Walks will coincide with Poster Q&A Sessions. During each session, an expert in the field will lead meeting attendees through the poster hall to view a curated selection of posters in each disease site. Poster Q&A Sessions features up to 150 posters in each track, so these Poster Walks give meeting attendees the opportunity to view a smaller collection of posters that more closely align with their interests. Attendees will listen to poster authors present their research, and have the opportunity to ask questions.

Meeting attendees do not sign up for the poster walk ahead of time. Instead, interested participants will meet Poster Walk leaders at the Concierge Desk in Exhibit Hall 1 before the start of the Poster Q&A Session

This event is a great opportunity for residents, early career radiation oncologists and first-time meeting attendees, giving them the opportunity to interface directly with poster authors and network with colleagues.


Poster Walk 1: Lung Cancer
Sunday, October 23, at 4:45 - 6:00 pm CT

Leader Jason Ye, MD
Location Screen 1

High-Dose Spatially Fractionated Radiotherapy, Lattice Radiotherapy in Bulky Tumors: Results after One Year Follow-Up

Whole Tumor vs. FDG-Directed Dose Escalation in Patients with Locally Advanced NSCLC: Evaluation of Isotoxic Treatment Plans from the Randomized ARTFORCE PET-Boost Trial

Widening the Therapeutic Window for Central and Ultra-Central Thoracic Oligometastatic Disease with Stereotactic MR-Guided Adaptive Radiation Therapy (SMART)

Prognostic Image Biomarkers in the Treatment of Patients with Locally Advanced NSCLC

Dynamic Change of Indoleamine 2,3-Dioxygenase Activity Predicts Survival in Radiotherapy-Received Unresectable Stage III NSCLC

Leader Greg Videtic, MD, FASTRO, CM, FRPC, FACR
Location Screen 8

Toxicity of Single-Fraction SABR for Non-Small Cell Lung Cancer

Real World Practice of Postoperative Radiotherapy for Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer

Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-Small Cell Lung Cancer: A Phase I/II Clinical Trial

Patterns of Failure in Resectable Stage I-IIIA NSCLC Treated with Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial

Mediastinal and Hilar Lymphadenopathy Treated by SABR

Leader Nitin Ohri, MD, MS
Location Screen 18

Association of Skeletal Muscle Area with Toxicity and Treatment Tolerance in Patients Receiving Chemoradiation for Advanced Lung CancerIncreasing Radiation Dose in the Setting of Treatment Prolongation for Stage III Non-Small Cell Lung Cancer (NSCLC)

Evaluating Radiation-Related Risk Factors for Pneumonitis in Patients with Stage III NSCLC Receiving Durvalumab after Definitive Chemoradiation

Tumor Mutational Burden Predicts Progression-Free Survival and Local-Regional Control in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Durvalumab

Salvage Re-Irradiation with Proton Beam Therapy for New or Locoregionally Recurrent Non-Small Cell Lung Cancer


Poster Walk 2: Central Nervous System
Monday, October 24, at 10:45 am - 12:00 pm CT

Leader Joshua Palmer, MD
Location Screen 18
Abstracts To Come

Poster Walk 3: Breast Cancer
Monday, October 24, at 3:00 - 4:00 pm CT

Leader Jennifer Bellon, MD, FASTRO
Location Screen 30

Effectiveness and toxicity of re-irradiation after breast conserving surgery for recurrent breast cancer

Impact of thyroid gland volume on the risk of developing post-rt hypothyroidism in breast cancer patients requiring comprehensive nodal radiation

21 gene recurrence score to select patients with t3N0 ER+ breast cancer likely to benefit with postmastectomy radiation

Risk of radiation dermatitis in patients with skin of color who undergo radiation to the breast or chest wall irradiation and regional lymph nodes 

Leader Christin Knowlton, MD
Location Screen 16

Accelerated Partial Breast Irradiation vs. Intraoperative Radiation Therapy for Early Stage Breast Cancer and Ductal Carcinoma In Situ

Safety and Feasibility of Simultaneous Integrated Boost in Extreme 1-Week Hypofractionated Radiotherapy for Early Breast Cancer

Radiation-Induced Acute Cardiotoxicity in Women with Left Sided Breast Cancer: Results from a Phase II Prospective Clinical Trial

Association of Treatment Arm with Quantitative Cosmetic Outcome in a Randomized Trial Comparing Whole Breast Irradiation Dosing Schedules

Leader Jose Bazan, MD
Location Screen 5

Are Diagnostic Computed Tomography Chest Scans Sufficient for Detecting Supraclavicular in Initial Breast Cancer Staging?

One-Year Toxicity of Ultrahypofractionated Breast Radiotherapy (+/- Sequential Boost) and a Survey of Patient Experience

Impact of Radiation Dosimetry and Clinical Factors on Implant-Based Breast Reconstruction Outcomes Following Post-Mastectomy Radiotherapy

Near-Maximum Rib Dose is the Most Relevant Risk Factor for Ipsilateral Spontaneous Rib Fracture: A Dosimetric Analysis of Breast Cancer Patients after Radiotherapy

Mediastinal and Hilar Lymphadenopathy Treated by SABR

Poster Walk 4: Biology
Monday, October 24, at 5:00 - 6:00 pm CT

Leader Corey Speers, MD, PhD
Location Screen 13

An In Vivo CRISPR Screening Platform to Evaluate the Therapeutic Impact of DNA Damage Response Gene Mutations

Correlation between Edic vs. Components of the Immune System Using Whole Breast plus Lymph Nodes, Partial Breast, Hypo- and Conventionally Fractionated Prostate Radiation Therapy

Gold Nanoparticle (AuNP) as a Therapeutic Enhancer for Radio – And Immunotherapy Therapy Combination in Triple Negative Breast Cancer

Quantifying the Abscopal Effect in Breast Cancer Using Granzyme B PET Imaging

Poster Walk 5: Gastrointestinal Cancer
Tuesday, October 25, at 12:45 - 2:00 pm CT

Leader Eric Miller, MD, PhD
Location Screen 6

Patient-Reported Bowel Function and Quality of Life Following Short and Long Course Radiotherapy for Locally Advanced Rectal Cancer

Necessity of External Iliac Lymph Nodes and Inguinal Nodes Radiation in Rectal Cancer with Anal Canal Involvement

Short-Course Radiotherapy Based Total Neoadjuvant Therapy Combined with Toripalimab for Locally Advanced Rectal Cancer: Preliminary Findings from a Randomized, Prospective, Multicenter, Double-Arm, Phase II Trial (TORCH)

The Treatment Outcomes of Oligometastatic Colorectal Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Multi-Institutional Analysis TROD 02-008

Risk-Adjusted Chemoradiation according to Human Papilloma Virus Status for Anal Cancer: A Pilot Registry Study

Leader Jeff Olsen, MD
Location Screen 22

Safety of Upfront Locoregional Therapy in Conjunction with Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Response and Survival in Patients of BCLC Stage C Hepatocellular Carcinoma Receiving SBRT and Immunotherapy

Impact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer

Dosimetric Predictors of Acute and Late Gastrointestinal Toxicities in Stereotactic Online Adaptive Magnetic Resonance-Guided Radiotherapy (SMART) for Locally Advanced Pancreatic Adenocarcinoma

Using Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients with Pancreatic Cancer: A Multi-Institutional Safety and Feasibility Study

Poster Walk 6: Genitourinary Cancer
Tuesday, October 25, 2:30 - 3:45 pm CT

Leader Mark Hurwitz, MD, FASTRO
Location Screen 2

Ten Year Follow-Up On 160 Patients Treated With Hypofractionated Prostate Salvage Radiation Therapy

Combined Brachytherapy and Ultra-Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer: Comparison of Toxicity Outcomes Using a High-Dose Rate (HDR) vs. Low-Dose Rate (LDR) Brachytherapy Boost

RTOG/NRG 1115 Quality of Life of Phase III Dose Escalated Radiation Therapy and Standard ADT with GnRH Agonist vs. Dose Escalated RT and ADT with GnRH Agonist and TAK-700

Cardiovascular Causes of Death in Patients Treated for Localized Prostate Cancer

Toxicity Analysis of Patients with Prostate Cancer Treated with 3-D Conformal Compared to IMRT: Secondary Analysis of RTOG 0126 and RTOG 0415

Leader Dabniel Hamstra, MD, PhD, FASTRO
Location Screen 30

The Maximum Standardized Uptake Value in Patients with Recurrent or Persistent Prostate Cancer after Radical Prostatectomy and PSMA-PET-Guided Salvage Radiotherapy – A Multicenter Retrospective Analysis

Randomized Trial of 18F-fluciclovine vs. 68Ga-PSMA PET/CT Guided Post-Prostatectomy Radiotherapy: Interim Volumetric and Toxicity Analyses

The Prognostic Value of the Size and the Sub-Site of the Local Failure at DCE-MRI before Salvage Radiotherapy for Prostate Cancer

The Accuracy of Multiparametric MRI in Identification of Intraprostatic Tumor Deposits after Local Prostate Radiation Therapy

Timing and Patterns of Potentially Salvageable Recurrences Following SBRT for Clinically Localized Prostate Cancer Assessed by Preferential Amino Acid Uptake

Leader W. Robert Lee, MD, MS, MEd, FASTRO
Location Screen 13

Characterizing the Performance of a Deep-Learning Segmentation Algorithm for Outlining Dominant Intraprostatic Lesions on Prostate Multi-Parametric MRI

Acute and Late Toxicity of Prostate-Only or Pelvic SBRT in Prostate Cancer: A Comparative Study

ReIGNITE RT Boost: An International Study Testing the Feasibility, Accuracy and Reliability of Using Restriction Spectrum Imaging (RSI) MRI to Guide Radiotherapy Target Volume Delineation for Prostate Cancer Tumor Boost

Prostate Magnetic Resonance Imaging Delta-Radiomics during Image-Guided Conventional Fractionation and Stereotactic Ablative Radiotherapy

Single Fraction HDR Brachytherapy for Prostate Cancer: SiFEPI Phase II Trial Results

Poster Walk 7: Pediatric Cancer
Tuesday, October 25, at 5:15 - 6:15 pm CT

Leader Luke Pater, MD
Location Screen 25

Multi-Institutional Investigation of Dose-Escalated Photon Radiotherapy for Intracranial Ependymoma

Dose Escalation for Posterior Fossa Ependymomas: Analysis of Prospective Pediatric Proton/Photon Consortium Registry

Incidence of Secondary Malignancy and Other Late Effects after Proton Radiotherapy for Retinoblastoma

Comprehensive Radiotherapy for Pediatric Ewing Sarcoma: Outcomes of a Prospective Proton Study

Poster Walk 8: Health Services Research
Wednesday, October 26, at 10:30 - 11:45 am CT

Leader Fukimo Chino, MD
Location Screen 21

Cancer Mortality and the 2014 Medicaid Expansions under the Affordable Care Act

Price Variability of Standard Radiotherapy Procedure Codes in a Large Metropolitan Area from 2015-2021

Online Adaptive Radiotherapy and Opportunity Cost

Defining the Cost Variation by Site-of-Care for Radiotherapy: A Claims-Based Analysis

Value-Based Cancer Care: How are We Training Future Radiation Oncologists on the Quality/Cost Equation?

Poster Walk 9: Head and Neck Cancer
Wednesday, October 26, at 10:30 - 11:45 am CT

Leader Henry Park, MD, MPH
Location Screen 8

The organs-at-risk dose constraints in head and neck intensity-modulated radiation therapy using data from a multi-institutional clinical trial (JCOG1015A1)

Chemotherapy and Radiation Dose Correlate with the Development of Hypothyroidism Following Radiation Therapy for Head and Neck Cancers

Prevalence and Functional Impact of Vertigo Among Long Term Survivors of Head and Neck Cancer

Surveillance With Electronic PROs and ctDNA in p16+ Oropharynx Cancer: Lessons From the Prospective FOCUS Registry (Follow up for HPV-related Oropharynx Cancer Concentrated on Symptom Change)

Development of Total Toxicity Burden Model in Head and Neck Cancer: Correlation of Clinician and Patient Reported Outcomes

Poster Walk 10: Physics
Wednesday, October 26, at 12:30 - 1:45 pm CT

Leader Jerry Soen, MS, DABR, FACN
Location Screen 31

Real-World Dose Delivery Accuracy of Prostate SBRT with Tomotherapy Based Target Tracking

Clinical LINAC-Based Electron FLASH: Pathway for Practical Translation to Trials of FLASH Radiotherapy

Feasibility of Using a Deep Learning Auto-Segmentation Software Trained with Planning CT for Iterative CBCT Based Online Adaptive Prostate Treatment

Systematic Study of Patient-Specific Organs at Risk Auto-Segmentation on Daily kVCT Images for Adaptive Head and Neck Radiotherapy

Daily Artificial Intelligence-Assisted Adaptive Radiotherapy on Cone-Beam CT for Cancer of the Head and Neck

If you are a poster presenter and are looking for more information about your presentation requirements, please navigate to the Speaker page.

American Society for Radiation Oncology
251 18th Street South, 8th Floor
Arlington, VA 22202
Telephone: 703-502-1550


Connect With Us: